TREA

Meridamycin analogues for the treatment of neurodegenerative disorders

Follow

Information

  • Patent Application
  • 20070213525
  • Publication Number
    20070213525
  • Date Filed
    March 05, 2007
    17 years ago
  • Date Published
    September 13, 2007
    17 years ago
Information
Abstract
A compound of the structure
Description
Claims
  • 1. A compound of the structure:
  • 2. The compound according to claim 1, wherein R1 and R2 are independently oxo, OH or O(acyl).
  • 3. The compound according to claim 2, wherein said O(acyl) is OC(O)CH3.
  • 4. The compound according to claim 1, wherein R3 and R4 or R4 and R5 are joined, wherein X and Y are CH3.
  • 5. The compound according to claim 1, wherein R7 is C(O).
  • 6. The compound according to claim 1 which is selected from the group consisting of:
  • 7. The compound according to claim 1, wherein R1 and R2 are OH; R3 and R4 are joined; R5 and R6 are joined; R7 is C(O); and n is 2
  • 8. The compound according to claim 1, wherein R1, R2, R3, R4, R5, and R6 are OC(O)CH3; R7 is C(O); and n is 2.
  • 9. The compound according to claim 1, wherein R1, R2, R3, and R4 are OC(O)CH3; R4 and R5 are OH; R7 is C(O); and n is 2.
  • 10. The compound according to claim 1, wherein R1, R2, R5, and R6 are OH; R3 and R4 are joined; R7 is C(O); and n is 2.
  • 11. The compound according to claim 1, wherein R1, R2, R3, R4, and R5 are OC(O)CH3; R6 is OH; R7 is C(O); and n is 2.
  • 12. The compound according to claim 1, wherein R1 and R2 are oxo; R3 and R4 and R5 and R6 are joined; R7 is C(O); and n is 2.
  • 13. The compound according to claim 1, wherein R1 and R2 are oxo; R3, R4, R5, and R6 are OH; R7 is C(O); and n is 2.
  • 14. The compound according to claim 1, wherein R1, R2, R3, and R6 are OH; R7 is C(O); n is 2; and R4 and R5 are taken together to form a ring of the structure:
  • 15. The compound according to claim 1, wherein R1, R2, R3 and R4 are OH; R7 is C(O); n is 2; and R5 and R6 are taken together to form a ring of the structure:
  • 16. A compound as claimed in claim 1, wherein R1 and R2 are, independently, OH, oxo, or O(acyl);R3, R4, R5, and R6 are independently selected from the group consisting of OH and O(acyl); orR3 and R4; R4 and R5; R5 and R6; or a combination thereof are joined to form a structure:—
  • 17. A composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable carriers, excipients, or diluents.
  • 18. A method of treating a mammal for a neurological disorder selected from the group consisting of epilepsy, stroke, cerebral ischemia, cerebral palsy, Alper's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, dementia with Lewy bodies, Rhett syndrome, neuropathic pain, spinal cord trauma, traumatic brain injury, senile dementias, mild cognitive impairment, or cognitive decline, comprising administering a composition according to claim 17 to a mammal.
  • 19. A method of preparing a compound of the structure:
  • 20. The method according to claim 19, wherein said alkylating agent is an alkyl halide, alkyl triflate, or alkyl mesylate.
  • 21. The method according to claim 19, wherein said alkyl anhydride is acetic anhydride.
  • 22. A method of preparing a compound of the structure:
  • 23. The method according to claim 22, wherein said dialkoxyalkane is 2,2-dimethoxypropane.
  • 24. The method according to claim 22, wherein said acid catalyst is paratoluenesulfonic acid.
  • 25. A method of preparing a compound of the structure:
  • 26. A method of preparing a compound of the structure:
  • 27. A method for preparing a compound of the structure:
  • 28. The method according to claim 27, wherein said weak acid is paratoluenesulfonic acid.
Provisional Applications (1)
Number Date Country
60779940 Mar 2006 US